Curix started in 2021 as an independent company, an own product company, within the Demcon group. This enabled the first developments towards a prototype injector that produces and administers microbubbles in a controlled manner. Once the initial concept had been successfully tested, the need for additional funding arose.
“A considerable investment was, and still is, needed to work towards clinical evaluations,” says Peter. “That's why we started looking for a party that could help us with this. The name Twinning came up in the Twente entrepreneurial network. We got in touch and presented our plans. The people at Twinning were enthusiastic and, after a thorough process in which we got to know each other better and better, they took a stake in Curix."
Committed partner
Twinning has become a very committed partner of Curix. Peter: “We are in close contact, and the people at Twinning are genuinely interested in our progress. Without breathing down our necks. They give us a lot of freedom and trust to continue developing our technology.”
Next step: clinical evaluations
The current seven members of the Curix team are passionately working on the transition to clinical trials. They are supported in this by engineers from DEMCON life sciences & health and receive funding and financial advice from Twinning Participaties. “Our goal is to conduct the first clinical study in 2027, in which we can test our technology on patients.”
Read the full article on Twinning Participaties: https://twinningparticipaties.nl/curix-twinning-is-betrokken-en-oprecht-geinteresseerd/
